Compare PFBC & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | OPK |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | 324 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | PFBC | OPK |
|---|---|---|
| Price | $104.49 | $1.48 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $102.67 | $1.60 |
| AVG Volume (30 Days) | 68.7K | ★ 4.4M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $8.31 | $4.24 |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $81.50 | $0.98 |
| 52 Week High | $112.26 | $1.73 |
| Indicator | PFBC | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 62.98 |
| Support Level | $104.01 | $1.25 |
| Resistance Level | $109.26 | $1.58 |
| Average True Range (ATR) | 1.97 | 0.06 |
| MACD | -0.40 | 0.02 |
| Stochastic Oscillator | 35.62 | 93.87 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.